A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730 · tracked via the Priya Life Science UK tracker

Sponsor

Verve Therapeutics, Inc.

Phase

Phase 1

Started

2024-04-30

Last updated

2026-09-02

Condition(s) studied

Heterozygous Familial HypercholesterolemiaPremature Coronary Heart Disease

Investigational drug(s) / intervention(s)

VERVE-102

VERVE-102: Intravenous (IV) infusion

Study summary

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: * Diagnosis of HeFH or premature CAD Exclusion Criteria: * Homozygous familial hypercholesterolemia * Active or history of chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol

Primary outcome measure(s)

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) — up to Day 365

Trial sites (27)

Facility	City	Region	Status
Clinical Study Center	Dothan	Alabama	Recruiting
Clinical Study Center	Pomona	California	Recruiting
Clinical Study Center	Boca Raton	Florida	Recruiting
Clinical Study Center	Jacksonville	Florida	Recruiting
Clinical Study Center	Winter Park	Florida	Recruiting
Clinical Study Center	Indianapolis	Indiana	Recruiting
Clinical Study Center	High Point	North Carolina	Recruiting
Clinical Study Center	Philadelphia	Pennsylvania	Recruiting
Clinical Study Center	DeSoto	Texas	Recruiting
Clinical Study Center	Renton	Washington	Recruiting
Clinical Study Center	Adelaide	Australia	Recruiting
Clinical Study Center	Melbourne	Australia	Recruiting
Clinical Study Center	Sydney	Australia	Recruiting
Clinical Study Center	Chicoutimi	Canada	Recruiting
Clinical Study Center	Hamilton	Canada	Recruiting
Clinical Study Center	Montreal	Canada	Recruiting
Clinical Study Center	Québec	Canada	Recruiting
Clinical Study Center	Toronto	Canada	Recruiting
Clinical Study Center	Vancouver	Canada	Recruiting
Clinical Study Center	Rehovot	Israel	Recruiting
Clinical Study Center	Christchurch	New Zealand	Recruiting
Clinical Study Center	Birmingham	United Kingdom	Recruiting
Clinical Study Center	Cambridge	United Kingdom	Recruiting
Clinical Study Center	Edinburgh	United Kingdom	Recruiting
Clinical Study Center	London	United Kingdom	Recruiting
Clinical Study Center	Manchester	United Kingdom	Recruiting
Clinical Study Center	Nottingham	United Kingdom	Recruiting

More Verve Therapeutics, Inc. trials in the UK

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia Recruiting

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease Enrolling by invitation

Other trials for the same condition

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06164730 on ClinicalTrials.gov ↗ ← All trials in the UK